Receive of Coq10

PreclinicalSmall molecule

IIslamic Azad University, Sanandaj

Receive of Coq10 is one of 31 small molecule programs targeting Chronic Periodontitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic PeriodontitisActive, not recruiting

Chronic PeriodontitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

65 competitors in Chronic Periodontitis

#DrugCompanyPhaseTrials

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

2 2

Singulair

OOrganon and Co

Approved

1 3

Minocin

TTriax

Approved

1 4

Crestor

AstraZeneca

Phase 3

3 5

Propolis

IIndonesia University

Approved

1 6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 7

Glucophage

EMD Serono

Phase 3

2 8

Fosamax

OOrganon and Co

Phase 3

2 9

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 10

IC-Green

CCHX Technologies Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Periodontitis1 trial

Non-surgical Treatment of Chronic Periodontitis With an Adjunctive Vitamin E and Coenzyme Q10 Supplementation

Enrolling by invitation·IIslamic Azad University, Sanandaj·N/A·NCT06373848·120 enrolled

Unspecified1 trial

CoQ10 and Omega-3 as Adjuncts to Periodontal Therapy, TAC of Saliva.

Enrolling by invitation·AAmirhossein Farahmand·N/A·NCT06358963·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Receive of Coq10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Receive of Coq10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Receive of Coq10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Islamic Azad University, Sanandaj company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IIslamic Azad University, Sanandaj

Receive of Coq10

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Periodontitis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News